


REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/US03/09225 into the U.S. National Phase of prosecution. In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Claims 7-15 have been amended to remove multiple dependencies, and claims 16-27 have been cancelled without prejudice or disclaimer.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090

N:\KLS\Cases\VP51332\NatI Stage\preliminary amendment.doc

P51332

ABSTRACT OF THE DISCLOSURE

Disclosed are methods of using compounds that modulate LXR.